Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients
mac lung disease alternative treatments :: Article Creator Inhaled Amikacin Shows Promise For Untreated MAC Lung Infections SAN DIEGO -- Adding amikacin liposome inhalation suspension (ALIS; Arikayce) to a macrolide-based regimen appeared to reduce respiratory symptoms and improve culture conversion rates in patients with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung infections, the randomized ARISE trial showed. As measured by the nine-item Quality of Life-Bronchiectasis Respiratory Domain (QOL-B RD), 43.8% of patients in the ALIS arm achieved a meaningful improvement in symptoms from baseline to 7 months, as compared with 33.3% of those assigned to the macrolide-based regimen plus placebo, reported Charles Daley, MD, of National Jewish Health and the University of Colorado School of Medicine in Denver. Culture conversion rates were numerically higher in the ALIS arm both following the 6-month period of daily treatment